Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
US-2026000758-A1 · Jan 1, 2026 · US
This page is not indexed by search engines while we improve data quality.
Glass David patents
Glass David is listed as an inventor on 46 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Glass David |
| Total patents | 46 |
| First publication | Jan 13, 2015 |
| Latest publication | Jan 1, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Engineered alpha klotho polypeptides and uses thereof
US-2025376667-A1 · Dec 11, 2025 · US
Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
US-2025277021-A1 · Sep 4, 2025 · US
Engineered alpha klotho polypeptides and uses thereof
US-2025154487-A1 · May 15, 2025 · US
Selective rapamycin analogs and uses thereof
US-2024360153-A1 · Oct 31, 2024 · US
Treatment of cancer using a cd123 chimeric antigen receptor
US-2023220090-A1 · Jul 13, 2023 · US
Methods Of Treating Clonal Hematopoiesis Of Indeterminate Potential (CHIP) With Lymphocyte Antigen 75 (LY75), Cluster Of Differentiation 164 (CD164), Or Poly(ADP-Ribose) Polymerase 1 (PARP1) Inhibitors
US-2023113866-A1 · Apr 13, 2023 · US
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
US-2023052970-A1 · Feb 16, 2023 · US
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US-11459390-B2 · Oct 4, 2022 · US
Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
US-2022056119-A1 · Feb 24, 2022 · US
Recent patents
Latest publications not already listed above.
Pharmaceutical combination of everolimus with dactolisib
US-2021030741-A1 · Feb 4, 2021 · US
Dual mode service WiFi access control
US-10708731-B2 · Jul 7, 2020 · US
Pharmaceutical combination of everolimus with dactolisib
US-10576076-B2 · Mar 3, 2020 · US
Treatment of cancer using a CLL-1 chimeric antigen receptor
US-10568947-B2 · Feb 25, 2020 · US
Low, immune enhancing, dose mtor inhibitors and uses thereof
US-2020054742-A1 · Feb 20, 2020 · US
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
US-10357514-B2 · Jul 23, 2019 · US
Dual mode service wifi access control
US-2019215666-A1 · Jul 11, 2019 · US
Low, immune enhancing, dose MTOR inhibitors and uses thereof
US-10286069-B2 · May 14, 2019 · US
Dual mode service WiFi access control
US-10278026-B2 · Apr 30, 2019 · US
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
US-10174095-B2 · Jan 8, 2019 · US
Low, immune enhancing, dose mtor inhibitors and uses thereof
US-2018369370-A1 · Dec 27, 2018 · US
Methods for b cell preconditioning in car therapy
US-2018334490-A1 · Nov 22, 2018 · US
Low, immune enhancing, dose mtor inhibitors and uses thereof
US-10004803-B2 · Jun 26, 2018 · US
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
US-2018118834-A1 · May 3, 2018 · US
Methods of treating Sporadic Inclusion Body Myositis
US-2018066061-A1 · Mar 8, 2018 · US
Treatment of cancer using a CD123 chimeric antigen receptor
US-9815901-B2 · Nov 14, 2017 · US
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US-2017306416-A1 · Oct 26, 2017 · US
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
US-2017274014-A1 · Sep 28, 2017 · US
Myostatin or activin antagonists for the treatment of sarcopenia
US-2017260275-A1 · Sep 14, 2017 · US
Methods and compositions using klotho-fgf fusion polypeptides
US-2017233446-A1 · Aug 17, 2017 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Novartis Ag | 30 |
| Glass David | 17 |
| Univ Pennsylvania | 14 |
| Mannick Joan | 10 |
| Murphy Leon | 10 |
Top CPC classifications
Most common classification codes across this inventor's patents.